Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog

Background. Loss of bone density with androgen deprivation therapy for prostate cancer is well recognized. We assessed the effects of quarterly infusion of zoledronic acid on bone mineral density (BMD) and markers of bone turnover over a one-year period in men receiving gonadotropin-releasing hormon...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapoor, Anoop, Gupta, Ankur, Desai, Nilay, Ahn, Hongshik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215945/
https://www.ncbi.nlm.nih.gov/pubmed/22110981
http://dx.doi.org/10.1155/2011/176164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215945/
https://www.ncbi.nlm.nih.gov/pubmed/22110981
http://dx.doi.org/10.1155/2011/176164

Ejemplares similares